AU2001259837A1 - Therapeutic pore-forming peptides - Google Patents

Therapeutic pore-forming peptides

Info

Publication number
AU2001259837A1
AU2001259837A1 AU2001259837A AU5983701A AU2001259837A1 AU 2001259837 A1 AU2001259837 A1 AU 2001259837A1 AU 2001259837 A AU2001259837 A AU 2001259837A AU 5983701 A AU5983701 A AU 5983701A AU 2001259837 A1 AU2001259837 A1 AU 2001259837A1
Authority
AU
Australia
Prior art keywords
pore
therapeutic
forming peptides
peptides
forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259837A
Inventor
Thomas E. Wagner
Xianxhang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greenville Hospital System
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Publication of AU2001259837A1 publication Critical patent/AU2001259837A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/823—Lower fungi, e.g. mold
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
AU2001259837A 2000-05-09 2001-05-09 Therapeutic pore-forming peptides Abandoned AU2001259837A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20306300P 2000-05-09 2000-05-09
US60203063 2000-05-09
US21204200P 2000-06-16 2000-06-16
US60212042 2000-06-16
PCT/US2001/040690 WO2001085777A2 (en) 2000-05-09 2001-05-09 Therapeutic pore-forming peptides

Publications (1)

Publication Number Publication Date
AU2001259837A1 true AU2001259837A1 (en) 2001-11-20

Family

ID=26898279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259837A Abandoned AU2001259837A1 (en) 2000-05-09 2001-05-09 Therapeutic pore-forming peptides

Country Status (6)

Country Link
US (2) US7094750B2 (en)
EP (1) EP1282642B1 (en)
AU (1) AU2001259837A1 (en)
CA (1) CA2411244A1 (en)
DE (1) DE60122873T2 (en)
WO (1) WO2001085777A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518142B1 (en) * 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
CA2517158A1 (en) * 2003-03-03 2004-09-16 University Of Victoria Innovation And Development Corporation Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
WO2005052158A1 (en) 2003-11-28 2005-06-09 National Research Council Of Canada Anticarcinoma antibidies and uses thereof
US7550426B2 (en) * 2005-05-18 2009-06-23 Ghc Research Development Corporation Acetylated therapeutic procytotoxins
WO2006128289A1 (en) * 2005-06-02 2006-12-07 University Of Manitoba Use of brevinin-2r in the treatment of cancer
ATE502954T1 (en) 2005-06-14 2011-04-15 Protox Therapeutics Inc METHOD FOR TREATING OR PREVENTING BENICAENT PROSTATE HYPERPLASIA USING MODIFIED PORE-FORMING PROTEINS
KR20070044868A (en) * 2005-10-26 2007-05-02 주식회사 바이오인프라 Recombinant adenovirus expressing a gene encoding streptolysin o protein and anti-cancer composition comprising same
US20090022799A1 (en) * 2006-10-06 2009-01-22 Shikha Pramanik Barman Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
WO2008085366A2 (en) * 2006-12-26 2008-07-17 President And Fellows Of Harvard College Methods and compositions for the killing of cells expressing human cd59
AU2010218261B2 (en) * 2009-02-26 2015-08-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
CN103145822A (en) * 2013-02-04 2013-06-12 中国科学院海洋研究所 Fish natural killer (NK)-lysin effective factors and application method thereof
CN103408650B (en) * 2013-07-26 2015-06-24 张朝晖 Cereus sinensis verrill soluble cell peptide CCT-I and separating and purifying method and application thereof
US10308693B2 (en) * 2015-02-22 2019-06-04 Omnix Medical Ltd. Antimicrobial peptides
WO2017182044A1 (en) * 2017-03-05 2017-10-26 Elawadan Khaled Mohy Eldin New modified synthetic peptides derived from honey proteins in cancer control
US20220281999A1 (en) * 2019-07-18 2022-09-08 National University Corporation Tokai National Higher Education And Research System Separated peptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
AU1086595A (en) * 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
AUPN861496A0 (en) 1996-03-13 1996-04-04 Commonwealth Scientific And Industrial Research Organisation Lytic peptides
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
AU7582298A (en) 1997-05-19 1998-12-11 Johns Hopkins University School Of Medicine, The Tissue specific prodrug
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
AU2003232077A1 (en) 2002-05-06 2003-11-17 The Scripps Research Institute Cyclic peptide anti-cancer agents and methods

Also Published As

Publication number Publication date
EP1282642A2 (en) 2003-02-12
US20050267031A1 (en) 2005-12-01
WO2001085777A2 (en) 2001-11-15
EP1282642B1 (en) 2006-09-06
US7425535B2 (en) 2008-09-16
DE60122873T2 (en) 2007-02-15
US7094750B2 (en) 2006-08-22
WO2001085777A3 (en) 2002-03-07
CA2411244A1 (en) 2001-11-15
US20020077454A1 (en) 2002-06-20
DE60122873D1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
GB0014870D0 (en) Peptides
AU2001259837A1 (en) Therapeutic pore-forming peptides
IL146832A0 (en) Peptides
AU2001284418A1 (en) Novel polypeptide
GB0100196D0 (en) Peptides
GB0029777D0 (en) Peptides
AU5836700A (en) Peptides for therapeutic use
EP1147130A4 (en) Alpha-conotoxin peptides
GB0109438D0 (en) Peptides
EP1159288A4 (en) Alpha-conotoxin peptides
GB0001825D0 (en) Peptides
AU2001244863A1 (en) Apoptin-associating protein
AU3774000A (en) Conformationally constrained peptides
AU2001278975A1 (en) Alpha-conotoxin peptides
GB0120713D0 (en) Peptides
AU2001277750A1 (en) Use of polypeptide
GB0007263D0 (en) Peptides
AU2001278777A1 (en) Irap-binding protein
AU2002224056A1 (en) Novel polypeptide
EP1151100A4 (en) Tau-conotoxin peptides
AU2001290317A1 (en) Novel peptides
AU2002328853A1 (en) Carcinoma-related peptides
AU2002215753A1 (en) Caml-binding peptides
AU2001263032A1 (en) Zsig33-like peptides
AU2001262806A1 (en) Peptides